-

Guardant Health to Participate in Upcoming November Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences:

  • Jefferies 14th Annual Global Healthcare Conference in London, UK
    Presentation on Thursday, November 16 at 9:00 a.m. Greenwich Mean Time
  • Piper Sandler 35th Annual Healthcare Conference in New York, NY
    Fireside Chat on Tuesday, November 28 at 9:30 a.m. Eastern Time

Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping every person live a life free from cancer. Founded in 2012, Guardant is transforming cancer care by providing critical insights into what drives the disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve patient outcomes across all stages of cancer, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).

Contacts

Investor Contact:
investors@guardanthealth.com

Media Contact:
Melissa Morasco
press@guardanthealth.com
+1 650-647-3711

Industry:

Guardant Health, Inc.

NASDAQ:GH
Release Versions
English

Contacts

Investor Contact:
investors@guardanthealth.com

Media Contact:
Melissa Morasco
press@guardanthealth.com
+1 650-647-3711

More News From Guardant Health, Inc.

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights For the three-month period ended June 30, 2026, as compared to the same period of 2025: Reported total revenue of $335.0 million, an increase of 44%, driven by: Oncology revenue of $219.1 million, an increase of 38%, and approximately 104,000 oncology tests, an increase of 63%...

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in Boston, MA Fireside chat on Wednesday, August 12th at 3:00 p.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY Fireside chat on Tuesday, September 15th at 7:45 a.m. Eastern Time Interested parties may access liv...

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will...
Back to Newsroom